Remus Pharmaceuticals Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/wa7hdhdyy14feqqrp2xk9s36.pdf

Key Takeaways


B2C Trajectory and the Launch-Delay Miss

Arpit Shah: "So, to contribute to the gap of 4%, to put it in that way, that were our expectations from the last year's growth on the B2C. Second is, we are comparing this with the total revenue. So, on our B2B, we've increased our share of sales a little. So, that also would give us a slightly lower on the B2C. What has changed for now is, the launch was delayed. It was not cancelled."

Margin Structure and the R&D Bet

Arpit Shah: "So, that is an access to the markets like Chile or Mexico, which I can brief you on it that these are the markets need bioequivalence studies and any product bioequivalence study is not that cheap. So, we have already filing in this market and for us, we will be having less competitors and of course, if we are having human clinical trials on that, we will have a better margin than not having the products with clinical trials."

Working Capital and the US Distribution Model


Pipeline Expansion: GLP-1, Biosimilars and Clinical Trial Services

Arpit Shah: "The government buys at a much cheaper cost than in the U.S. And always the government has this preference that they will buy a product which is U.S. approved even at a 2x price. So, that will also be a beneficial model for us."

Geographical and Therapeutic Expansion


Business Model Defense

Arpit Shah: "If this was a trading business, my gross margin wouldn't have been anywhere between 55% to 60%. This is a very organized business model that we have been doing where the products are registered. The registration is not a week or two weeks or four weeks' timeline. The registration is between six months to two years or three years."

Guidance & Commitments

CommitmentSpecificsTimeline
B2C revenue shareAt least 30% of total revenue from B2C, with double growth on B2CFY27
B2B topline growth25-30% growth from revenue perspectiveFY27
Delayed launch conversionLaunches delayed from Q4 to give a bump-upQ1 FY27
Bolivia B2C launchesAdditional 40 products launchedNext 2-3 months
Peru product filings60 products filed, with commercializationThis financial year
Semaglutide commercializationLaunch in 3-4 non-patented countries where filings are doneThis year
Margin improvementStandalone PAT margins to improve as B2C scales to 30%; consolidated margins to lift as Algeria, Mexico, Chile become revenue runnersNext 1-1.5 years
Espee Global Clinical Trial ServicesOperational, partially adding to margins this year, fully from next yearAnytime this year
Nicaragua tender recurrenceCeftazidime Avibactam order expected every quarter or twoOngoing
Debtor daysReduction expected as company moves to new regionsUndated

Key Metrics

MetricFY26 / H2 FY26
Consolidated revenue (FY26)₹854 cr, 38% YoY growth
Consolidated revenue (H2 FY26)₹453 cr, 30% YoY growth
Standalone revenue (H2 FY26)₹47 cr, 14% YoY growth
Consolidated EBITDA (FY26)₹57 cr, 24% YoY growth
Consolidated EBITDA margin (H2 FY26)6.57%
Standalone EBITDA margin (H2 FY26)31.85%
Consolidated net profit (FY26)₹46 cr, 20% YoY growth
Net profit attributable to holding company (FY26)₹37 cr, 27% YoY growth
Standalone PAT margin (H2 FY26)26.96%
B2C revenue contribution14% of total revenue, up from 4% last year
B2B revenue contribution86% of total revenue
B2C growth target (FY27)at least 30% from total revenue perspective
B2B growth target (FY27)25%–30% from revenue perspective
R&D investment (FY26)~₹3–4 cr, impacting consolidated margins
Consolidated operating cash flow (FY26)~₹18 cr
Standalone operating cash flow (FY26)~₹25 cr
Gross margin (finished formulations business)55%–60%
Countries of operation40+ countries for export of finished formulations
Products launched in Bolivia (B2C)26 products launched, 40 additional planned in next 2–3 months
Products planned for filing in Peru60 products in three months
Brand names and trademarks registered for B2C126
Active manufacturing partners~20 actively, 34 approved
Shipment mode30%–35% by sea, rest by air
Advance payment range25%–50% in most cases
Inventory buffer for chronic products4–5 months minimum, not exceeding 6 months